75 related articles for article (PubMed ID: 22252185)
41. [Clonal evolution of abnormal Philadelphia chromosome-negative cells after imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia].
Jiang Q; Chen SS; Jiang B; Jiang H; Lu Y; Qiu JY; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):23-6. PubMed ID: 15946504
[TBL] [Abstract][Full Text] [Related]
42. The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations.
Mohamed AN; Pemberton P; Zonder J; Schiffer CA
Clin Cancer Res; 2003 Apr; 9(4):1333-7. PubMed ID: 12684401
[TBL] [Abstract][Full Text] [Related]
43. [Therapeutic effects of imatinib on chronic myeloid leukemia in different phases and the factors affecting the effects].
Zou WY; Xu DR; Su C; Li J; Luo SK
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug; 28(9):1660-2. PubMed ID: 18819894
[TBL] [Abstract][Full Text] [Related]
44. Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia.
Kantarjian HM; Talpaz M; Cortes J; O'Brien S; Faderl S; Thomas D; Giles F; Rios MB; Shan J; Arlinghaus R
Clin Cancer Res; 2003 Jan; 9(1):160-6. PubMed ID: 12538464
[TBL] [Abstract][Full Text] [Related]
45. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
DeAngelo DJ; Hochberg EP; Alyea EP; Longtine J; Lee S; Galinsky I; Parekkedon B; Ritz J; Antin JH; Stone RM; Soiffer RJ
Clin Cancer Res; 2004 Aug; 10(15):5065-71. PubMed ID: 15297408
[TBL] [Abstract][Full Text] [Related]
46. Treatment of chronic myeloid leukemia in the imatinib era: perspective from a developing country.
Aziz Z; Iqbal J; Akram M; Saeed S
Cancer; 2007 Mar; 109(6):1138-45. PubMed ID: 17315159
[TBL] [Abstract][Full Text] [Related]
47. Dual inhibition of ras and bcr-abl signalling pathways in chronic myeloid leukaemia: a phase I/II study in patients in complete haematological remission.
Pavlu J; Andreasson C; Chuah C; Kaeda J; Goldman JM; Apperley JF; Marin D
Br J Haematol; 2007 Jun; 137(5):423-8. PubMed ID: 17428238
[TBL] [Abstract][Full Text] [Related]
48. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up.
Palandri F; Castagnetti F; Testoni N; Luatti S; Marzocchi G; Bassi S; Breccia M; Alimena G; Pungolino E; Rege-Cambrin G; Varaldo R; Miglino M; Specchia G; Zuffa E; Ferrara F; Bocchia M; Saglio G; Pane F; Alberti D; Martinelli G; Baccarani M; Rosti G;
Haematologica; 2008 Dec; 93(12):1792-6. PubMed ID: 18838477
[TBL] [Abstract][Full Text] [Related]
49. The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells.
Deininger MW; Cortes J; Paquette R; Park B; Hochhaus A; Baccarani M; Stone R; Fischer T; Kantarjian H; Niederwieser D; Gambacorti-Passerini C; So C; Gathmann I; Goldman JM; Smith D; Druker BJ; Guilhot F
Cancer; 2007 Oct; 110(7):1509-19. PubMed ID: 17702093
[TBL] [Abstract][Full Text] [Related]
50. Acute myeloid leukemia developing during imatinib mesylate therapy for chronic myeloid leukemia in the absence of new cytogenetic abnormalities.
Pawarode A; Sait SN; Nganga A; Coignet LJ; Barcos M; Baer MR
Leuk Res; 2007 Nov; 31(11):1589-92. PubMed ID: 17391756
[TBL] [Abstract][Full Text] [Related]
51. Chronic myelogenous leukemia in T cell lymphoid blastic phase achieving durable complete cytogenetic and molecular remission with imatinib mesylate (STI571; Gleevec) therapy.
Atallah E; Talpaz M; O'brien S; Rios MB; Guo JQ; Arlinghaus R; Fernandes-Reese S; Kantarjian H
Cancer; 2002 Jun; 94(11):2996-9. PubMed ID: 12115389
[TBL] [Abstract][Full Text] [Related]
52. Granulocytic sarcoma in a patient with chronic myeloid leukaemia in complete haematological, cytogenetic and molecular remission.
Kittai A; Yu EM; Tabbara I
BMJ Case Rep; 2014 Dec; 2014():. PubMed ID: 25538217
[TBL] [Abstract][Full Text] [Related]
53. Study on adherence to treatment with imatinib in chronic myeloid leukaemia and its association with therapeutic response.
García-Queiruga M; Martínez-López LM; Martín-Herranz MI; Seoane-Pillado T; Fernández-Gabriel E; Calleja-Chuclá T
Farm Hosp; 2016 May; 40(3):141-9. PubMed ID: 27145384
[TBL] [Abstract][Full Text] [Related]
54. Life-threatening haematological disorders presenting with opthalmic manifestations.
Wechsler DZ; Tay TS; McKay DL
Clin Exp Ophthalmol; 2004 Oct; 32(5):547-50. PubMed ID: 15498074
[TBL] [Abstract][Full Text] [Related]
55. Chronic myeloid leukaemia: A qualitative interview study exploring disease impact from patient and practitioner perspectives.
Hewison A; Roman E; Smith A; McCaughan D; Sheridan R; Patmore R; Atkin K; Howell D
Eur J Oncol Nurs; 2023 Dec; 67():102421. PubMed ID: 37804754
[TBL] [Abstract][Full Text] [Related]
56. Uncommon Haematological Transformation: Chronic Myeloid Leukaemia Transitioning Into Plasma Cell Leukaemia in a Single Patient.
Jain MA; Acharya S; Pal AS; Raut L
Cureus; 2024 Jan; 16(1):e51639. PubMed ID: 38318562
[TBL] [Abstract][Full Text] [Related]
57. The Relative Efficacy of Treatments in First-Line Management of Newly Diagnosed Chronic Myeloid Leukaemia: Systematic Literature Review and Indirect Comparison.
Kroes M; Zagorska A; Osei-Assibey G; Paine A
Value Health; 2014 Nov; 17(7):A615. PubMed ID: 27202156
[No Abstract] [Full Text] [Related]
58. Retraction: Carboxyamidotriazole-Orotate Inhibits the Growth of Imatinib-Resistant Chronic Myeloid Leukaemia Cells and Modulates Exosomes-Stimulated Angiogenesis.
PLOS ONE Editors
PLoS One; 2019; 14(10):e0224237. PubMed ID: 31618259
[No Abstract] [Full Text] [Related]
59. NOTES OF A CASE OF "NODULAR LEUKAEMIA.".
Reid R; Calwell W; Thomson WW
Br Med J; 1913 Jun; 1(2738):1318-9. PubMed ID: 20766696
[No Abstract] [Full Text] [Related]
60. Medication-related issues associated with adherence to long-term tyrosine kinase inhibitors for controlling chronic myeloid leukemia: a qualitative study.
Tan BK; Tan SB; Chen LC; Chang KM; Chua SS; Balashanker S; Kamarul Jaman HNB; Edmund SC; Bee PC
Patient Prefer Adherence; 2017; 11():1027-1034. PubMed ID: 28652712
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
